Edward van Wezel
Founder and Managing Partner @ BioGeneration Ventures
Naarden, The Netherlands
Edward van Wezel is a Series A investor at BioGeneration Ventures in Naarden focused on Health Care and Biotechnology. Edward van Wezel is based out of Naarden, North Holland and is the Founder and Managing Partner of BioGeneration Ventures. Edward previously worked at TigaTx as a Director. Edward van Wezel attended the Utrecht University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Edward van Wezel invests in
Stages Edward van Wezel invests in
Countries Edward van Wezel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (33%)
- Biotechnology 3 (33%)
- Medical 2 (22%)
- Therapeutics 2 (22%)
- Biopharma 1 (11%)
Stage
- Series A 3 (33%)
- Series B 3 (33%)
- Seed 1 (11%)
- Funding Round 1 (11%)
Country
- The Netherlands 4 (44%)
- Belgium 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding. | $58M / Series A / Oct 06, 2026 | ||
| Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M / Series B / May 13, 2025 | ||
| Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands. | $89.7M / Series B / Dec 09, 2024 | ||
| Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M / Series B / Jul 26, 2024 | ||
| Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands. | $20.8M / Series B / Jul 02, 2020 | ||
| Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $27.5M / Series A / Feb 06, 2020 | ||
| Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $33.6M / Series A / May 07, 2019 | ||
| Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | Seed / Jul 23, 2018 | ||
| NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnosticassays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stages of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland. |
Co-Investors
About BioGeneration Ventures
BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands. BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies. The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond the financial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company's technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.
BioGeneration Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniela Couto
General Partner
|
|||
|
Edward van Wezel
Founder and Managing Partner
|
|||
Joost Holthuis
Venture Partner
|
|||
Oskar Slotboom
Managing Partner
|
|||
Elena Ritsou
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edward van Wezel invest in?
Edward van Wezel invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Edward van Wezel?
Public channels for Edward van Wezel include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Edward van Wezel last invest?
The most recent investment recorded for Edward van Wezel closed in Oct 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
